UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 4, 2003
PRO-PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada
(State or Other Jurisdiction of Incorporation)
| 000-32877 |
04-3562325 | |
| (Commission File Number) | (IRS Employer Identification No.) | |
| 189 Wells Avenue, Newton, Massachusetts |
02459 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
(617) 559-0033
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Item 5. Other Events and Regulation FD Disclosure
On November 4, 2003 and November 11, 2003, respectively, the U.S. Patent and Trademark Office issued the following U.S. patents covering the Company’s core carbohydrate drug targeting and delivery platforms: (i) No. 6,642,205. “Methods and Compositions for Reducing Side Effects in Chemotherapeutic Treatments” and (ii) No. 6,645,946. “Delivery of a Therapeutic Agent in a Formulation for Reduced Toxicity.”
Item 7. Financial Statements and Exhibits
(c) Exhibits.
99.1 Press Release of Pro-Pharmaceuticals, Inc. dated November 13, 2003
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PRO-PHARMACEUTICALS, INC. | ||
| By: |
/s/ David Platt, Ph.D | |
| David Platt. Ph.D President and Chief Executive Officer | ||
Date: November 14, 2003
3